Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Tripathy on Ixabepilone in Patients With TNBC

March 13th 2016

Debu Tripathy, MD, chair, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the use of ixabepilone as a treatment for patients with triple-negative breast cancer (TNBC).

Genomic Profiling of DCIS Is Ready for Prime Time

March 13th 2016

There is a subset of low-risk patients with ductal carcinoma in situ for whom surgery alone is optimal and the Oncotype DX DCIS Score is a useful assay for identifying these individuals.

Despite Setbacks, pCR Still Acceptable for Breast Cancer Approvals

March 13th 2016

Pathologic complete response may still have a role in accelerated neoadjuvant approvals for select patients with early stage breast cancer, despite the fact that it remains an unproven surrogate endpoint.

Amy Robach on Factors Impacting Her Breast Cancer Treatment Decision

March 12th 2016

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.

Alpelisib Combo Promising in PIK3CA-Altered, Heavily Pretreated Breast Cancer

March 12th 2016

The combination of the alpha-specific PI3K inhibitor alpelisib (BYL719) and fulvestrant (Faslodex) demonstrated promising early efficacy and mild toxicity in heavily pretreated postmenopausal women with ER-positive metastatic breast cancer.

Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBC

March 12th 2016

Among patients with HR+/HER2- or triple-negative metastatic breast cancer, nab-paclitaxel (Abraxane) improved time to treatment discontinuation, time to next treatment, and had a favorable safety profile compared with paclitaxel.

More Data Needed to Confirm Early Results on Carboplatin in TNBC

March 11th 2016

Carboplatin shows promise in treating metastatic BRCA-mutated triple negative breast cancer.

Dr. Symmans on Moon Shots Program for Patients With TNBC

March 11th 2016

William F. Symmans, MB, ChB, Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas MD Anderson Cancer Center, discusses the institution's Moon Shots program for patients with triple-negative breast cancer.

Dr. Blackwell on Late Recurrences in Patients With Breast Cancer

March 10th 2016

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses using the word "cure" in patients with breast cancer who have not had recurrences of disease.

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

March 9th 2016

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Key Studies Help Chart Course in HER2-Positive Breast Cancer

February 28th 2016

Among the bright spots in the treatment of patients with breast cancer are the successes achieved in the management of HER2-positive disease. And, therapeutic options are continuing to expand, owing to the advent of novel anti-HER2â€“targeted agents and multitargeted HER2 receptor blockade.

Blackwell on Recent Advances in HER2-Positive Breast Cancer

February 25th 2016

Kimberly L. Blackwell, MD, discusses recent studies examining emerging agents in HER2-positive breast cancer.

Dr. Erika P. Hamilton on ONT-380 for HER2+ Breast Cancer

February 25th 2016

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research Program; Principal Investigator, Sarah Cannon Research Institute, discusses ONT-380, a novel HER2-specific inhibitor. Most oral HER2-inhibitors block not only HER2, but other proteins such as EGFR.

FDA Approves Palbociclib in Pretreated HR+/HER2-Negative Breast Cancer

February 19th 2016

The FDA has approved palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.

Dr. Benjamin D. Smith on Mastectomy Versus Lumpectomy for Early Breast Cancer

February 19th 2016

Benjamin D. Smith, MD, associate professor and research director of breast radiation oncology, The University of Texas MD Anderson Cancer Center, Houston, discusses complications with mastectomy versus lumpectomy for early breast cancer.

Searching for Possibilities, Hortobagyi Found Greatness

February 17th 2016

Gabriel N. Hortobagyi, MD, who has pioneered many clinical advances in the treatment of women with breast cancer, was honored in the Breast Cancer category with a 2015 Giants of Cancer CareÂ® award, a program that the IntellisphereÂ® Oncology Specialty Group launched to honor leaders in the field.

Breast Cancer Research Sheds New Light on HR-Positive Disease

February 16th 2016

Although metastatic breast cancer remains incurable for most women, recent research offers important new guidance for clinicians managing patients across the spectrum of advanced disease.

Immunology Biomarkers Taking Shape in Breast Cancer

February 15th 2016

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes.

ASCO Guideline Clarifies Biomarker Assay Use in Adjuvant Breast Cancer Care

February 8th 2016

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

FDA Grants Antibody-Drug Conjugate Breakthrough Designation in TNBC

February 5th 2016

Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.